Alex Ekwume Federal University Teaching Hospital Abakaliki, Ebonyi State, Nigeria.
Department of Surgery, University of Calabar, Nigeria.
Medicine (Baltimore). 2023 Nov 24;102(47):e35910. doi: 10.1097/MD.0000000000035910.
Appropriate usage of highly active antiretroviral therapy (HAART) suppresses human immunodeficiency virus (HIV) replication. One of such HAART is dolutegravir (DTG) containing regimen which Nigeria included in her national protocol, as the preferred first-line option, with particularly fixed dose combination of tenofovir/lamivudine/dolutegravir (TLD) in 2018.
To access the impact of this regimen as against other regimens on some hematological parameters as well as cluster of differentiation 4 (CD4) count and viral load on people living with HIV infection.
The study site is a health facility center supported by President Emergency Plan for acquired immunodeficiency syndrome (AIDS) Relief where people living with HIV infection (PLWHIV) visit for their routine management in Abakaliki, Ebonyi State. A hundred and twenty-two (122) subjects participated, 58 PLWHIV and 64 control subjects. CD4 + count by partec cyflow auto analyzer, while the Viral load assay was by Roche COBAS Ampriplep/COBAS TaqMan molecular systems. Full blood count determination was by Sysmex XE-2100 hematology auto analyzer, while the detection of antibody to HAART was by Petz and direct Coombs tests.
Mean values of hemoglobin (Hb), Total white cell count, Lymphocytes, Monocytes and CD4 + counts of people living with HIV infection (PLWHIV) were significantly (P = .0001) lower than the control subjects. The Hb level of PLWHIV on Efavirenz combination (TDF/3TC/EFV) are comparable 123 ± 32g/l with those on Ritonavir combination (TDF/3TC/LPV/R) 136 ± 16g/l and Dolutegravir (TLD)134 ± 20.0g/l (P = .307). On the other hand, total white cell count (4.55 ± 1.99 × 109/L) of those on Efavirenz combination (TDF/3TC/EFV) and Dolutegravir (TLD) (4.53 ± 1.31 × 109/L) were significantly higher than those on Ritonavir combination (TDF/3TC/LPV/R) (4.09 ± 1.15 × 109/L). The Viral Load of PLWHIV on Dolutegravir (TLD) was significantly lower 171.57 ± 4.56 copies/mL than those on Efavirenz combination (TDF/3TC/EFV) (86,395.91 ± 27,476.57copies/mL) and Ritonavir combination (TDF/3TC/LPV/R) (81,188.83 ± 13,393.47 copies/mL), respectively.
Some hematological parameters (such as Hb, total white cell counts and CD4 + count) were lower in people living with HIV than values seen in control group. The 3 regimens used in the management of HIV infection in the locality revealed comparable Packed cell volume and Hemoglobin levels. Total white cell count of those on Efavirenz and DTG is comparable with higher values than those on Ritonavir.
高效抗逆转录病毒疗法(HAART)的合理使用可抑制人类免疫缺陷病毒(HIV)的复制。其中一种 HAART 是含有度鲁特韦(DTG)的方案,尼日利亚于 2018 年将其纳入国家方案,作为首选的一线治疗方案,特别是含有替诺福韦/拉米夫定/度鲁特韦(TLD)的固定剂量复方。
评估该方案与其他方案相比,对一些血液学参数以及 CD4+计数和 HIV 感染者的病毒载量的影响。
研究地点是一个由总统艾滋病紧急救援计划(AIDS)支持的医疗设施中心,HIV 感染者(PLWHIV)在埃邦伊州阿巴卡利基的常规管理中访问该中心。共有 122 名受试者参与,其中 58 名 PLWHIV 和 64 名对照受试者。通过 partec cyflow 自动分析仪检测 CD4+计数,罗氏 COBAS Ampriplep/COBAS TaqMan 分子系统检测病毒载量。Sysmex XE-2100 血液学自动分析仪测定全血细胞计数,Petz 和直接 Coombs 试验检测抗 HAART 抗体。
HIV 感染者(PLWHIV)的血红蛋白(Hb)、总白细胞计数、淋巴细胞、单核细胞和 CD4+计数的平均值明显(P=0.0001)低于对照组。接受依非韦伦联合方案(TDF/3TC/EFV)的 PLWHIV 的 Hb 水平为 123±32g/L,与接受利托那韦联合方案(TDF/3TC/LPV/R)的 136±16g/L 和度鲁特韦(TLD)的 134±20.0g/L 相当(P=0.307)。另一方面,接受依非韦伦联合方案(TDF/3TC/EFV)和度鲁特韦(TLD)的总白细胞计数(4.55±1.99×109/L)明显高于接受利托那韦联合方案(TDF/3TC/LPV/R)的总白细胞计数(4.09±1.15×109/L)。接受度鲁特韦(TLD)治疗的 PLWHIV 的病毒载量明显较低,为 171.57±4.56 拷贝/mL,明显低于接受依非韦伦联合方案(TDF/3TC/EFV)(86395.91±27476.57 拷贝/mL)和利托那韦联合方案(TDF/3TC/LPV/R)(81188.83±13393.47 拷贝/mL)。
与对照组相比,HIV 感染者的一些血液学参数(如 Hb、总白细胞计数和 CD4+计数)较低。在当地管理 HIV 感染中使用的 3 种方案显示出类似的红细胞压积和血红蛋白水平。接受依非韦伦和 DTG 治疗的患者的总白细胞计数与接受利托那韦治疗的患者相当,且数值更高。